ThePrint on MSN3d
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...
The Lancet7d
The impact of the US election on diabetes
The overwhelming support for Donald Trump on Nov 5, 2024, for the US presidential election, came as a surprise to many. The impact of the US election outcome on public health in general, and womens' ...